HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma

Alaa M Afify, Bruce A. Werness, Hon Fong L Mark

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Oncogene amplification has been implicated in the genesis and progression of many cancers. Overexpression of the HER-2/neu proto-oncogene occurs in 20-30% of ovarian epithelial cancers, in which it may be of prognostic significance. Oncogene overexpression is traditionally studied using immunohistochemistry. In this study we used fluorescent in situ hybridization (FISH) to determine HER-2/neu amplification in ovarian papillary serous carcinoma and compared the frequency of amplification in two stages of the disease. Archival tissues from 23 cases of papillary serous ovarian carcinoma (9 cases of stage I and 14 cases of stage III) were analyzed by FISH using a HER-2/neu probe and a chromosome 17 centromere control probe. Determination of the level of amplification was performed according to the standard protocols of the Cytogenetics Laboratory at Rhode Island Hospital. Of the 23 cases successfully analyzed, the frequency of amplification among stage I tumors was 22% (2/9) and the frequency of amplification among stage III tumors was 71% (10/14). These results are significant (P = 0.036). The frequency of stage I tumors among amplified cases was 17% (2/12) and the frequency of stage III tumors among amplified cases was 83% (10/12). This study not only confirms the presence of a subset of ovarian papillary serous carcinoma with HER-2/neu gene amplification, but it also indicates that HER-2/neu oncogene amplification is more likely to be associated with a more advanced stage. Thus, the present data are consistent with the hypothesis that HER-2/neu amplification, similar to HER-2/neu protein overexpression, is a prognostic marker of poor outcome.

Original languageEnglish (US)
Pages (from-to)163-169
Number of pages7
JournalExperimental and Molecular Pathology
Issue number2
StatePublished - Jun 1999
Externally publishedYes


  • Fluorescent in situ hybridization
  • HER-2/neu oncogene amplification
  • Ovarian cancer

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Pathology and Forensic Medicine


Dive into the research topics of 'HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma'. Together they form a unique fingerprint.

Cite this